These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 24640618)

  • 21. Who's on third? Regulation of third-party genetic interpretation services.
    Guerrini CJ; Wagner JK; Nelson SC; Javitt GH; McGuire AL
    Genet Med; 2020 Jan; 22(1):4-11. PubMed ID: 31402353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Limitations of direct-to-consumer advertising for clinical genetic testing.
    Gollust SE; Hull SC; Wilfond BS
    JAMA; 2002 Oct; 288(14):1762-7. PubMed ID: 12365961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ensuring that consumers receive appropriate information from drug ads: what is the FDA's role?
    Waxman HA
    Health Aff (Millwood); 2004; Suppl Web Exclusives():W4-256-8. PubMed ID: 15452002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "It's our DNA, we deserve the right to test!" A content analysis of a petition for the right to access direct-to-consumer genetic testing.
    Su Y; Borry P; Otte IC; Howard HC
    Per Med; 2013 Sep; 10(7):729-739. PubMed ID: 29768761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. "I would rather have it done by a doctor"-laypeople's perceptions of direct-to-consumer genetic testing (DTC GT) and its ethical implications.
    Schaper M; Wöhlke S; Schicktanz S
    Med Health Care Philos; 2019 Mar; 22(1):31-40. PubMed ID: 29705970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prescription drug advertising: is it a driving force on drug pricing?
    Millstein LG
    N C Med J; 2003; 64(6):289-91. PubMed ID: 14983621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. "Be ready against cancer, now": direct-to-consumer advertising for genetic testing.
    William-Jones B
    New Genet Soc; 2006 Apr; 25(1):89-107. PubMed ID: 17312631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DTC genetic testing: pendulum swings and policy paradoxes.
    Caulfield T
    Clin Genet; 2012 Jan; 81(1):4-6. PubMed ID: 21999657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Problems associated with direct-to-consumer advertising (DTCA) of restricted, implantable medical devices: should the current regulatory approach be changed?
    Patsner B
    Food Drug Law J; 2009; 64(1):1-41. PubMed ID: 19998571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct-to-Consumer Genetic Testing: Finding a Clear Path Forward.
    Seward B
    Ther Innov Regul Sci; 2018 Jul; 52(4):482-488. PubMed ID: 29714553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ASHG Statement* on direct-to-consumer genetic testing in the United States.
    Hudson K; Javitt G; Burke W; Byers P;
    Obstet Gynecol; 2007 Dec; 110(6):1392-5. PubMed ID: 18055737
    [No Abstract]   [Full Text] [Related]  

  • 33. The future of direct-to-consumer clinical genetic tests.
    Frueh FW; Greely HT; Green RC; Hogarth S; Siegel S
    Nat Rev Genet; 2011 Jun; 12(7):511-5. PubMed ID: 21629275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Supplemental Security Income for the Aged, Blind and Disabled (SSI) program demonstration project; treatment of cash received and conserved to pay for medical or social services--SSA. Notice.
    Fed Regist; 1998 Nov; 63(211):58802-4. PubMed ID: 10185853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Which lessons can we learn from the European Union legal framework of medicines for the regulation of direct-to-consumer genetic tests?
    van Hellemondt R; Hendriks A; Breuning M
    Rev Derecho Genoma Hum; 2012; (36):99-120. PubMed ID: 23115825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct-to-consumer testing: more risks than opportunities.
    Lippi G; Favaloro EJ; Plebani M
    Int J Clin Pract; 2011 Dec; 65(12):1221-9. PubMed ID: 22093530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA recognition of consensus standards in the premarket notification program.
    Marlowe DE; Phillips PJ
    Biomed Instrum Technol; 1998; 32(3):301-4. PubMed ID: 9619259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transparency of genetic testing services for 'health, wellness and lifestyle': analysis of online prepurchase information for UK consumers.
    Hall JA; Gertz R; Amato J; Pagliari C
    Eur J Hum Genet; 2017 Aug; 25(8):908-917. PubMed ID: 28703222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating online direct-to-consumer marketing of genetic tests: informed choices or buyers beware?
    Geransar R; Einsiedel E
    Genet Test; 2008 Mar; 12(1):13-23. PubMed ID: 18373401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medicine, market and communication: ethical considerations in regard to persuasive communication in direct-to-consumer genetic testing services.
    Schaper M; Schicktanz S
    BMC Med Ethics; 2018 Jun; 19(1):56. PubMed ID: 29871685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.